1. Mansour Razavi S, Salamati P, Saghafinia M, Abdollahi M. A review on delayed toxic effects of sulfur mustard in Iranian veterans. DARU Journal of Pharmaceutical Sciences 2012;20(1):51.
2. Emami MH, Talaei M, Panahi Y, Saburi A, Ghanei M. Efficacy of omeprazole on cough, pulmonary function and quality of life of patients with sulfur mustard lung injury: A placebo-control, cross-over clinical trial study. Journal of Research in Medical Sciences: The official Journal of Isfahan University of Medical Sciences 2014;19(11):1027.
3. Imani S, Salimian J, Fu J, Ghanei M, Panahi Y. Th17/Treg-related cytokine imbalance in sulfur mustard exposed and stable chronic obstructive pulmonary (COPD) patients: correlation with disease activity. Immunopharmacology and Immunotoxicology 2016;38(4):270-80.
4. Emad A, Emad Y. Levels of cytokine in bronchoalveolar lavage (BAL) fluid in patients with pulmonary fibrosis due to sulfur mustard gas inhalation. Journal of Interferon & Cytokine Research 2007;27(1):38-43.
5. Ghazanfari T, Kariminia A, Yaraee R, Faghihzadeh S, Ardestani SK, Ebtekar M, et al. Long term impact of sulfur mustard exposure on peripheral blood mononuclear subpopulations—Sardasht-Iran Cohort Study (SICS). International Immunopharmacology 2013;17(3):931-5.
6. Shaker Z, Hassan Z, Sohrabpoor H, Mosaffa N. The immunostatus of T helper and T cytotoxic cells in the patients ten years after exposure to sulfur mustard. Immunopharmacology and Immunotoxicology 2003;25(3):423-30.
7. Imani S, Salimian J, Bozorgmehr M, Vahedi E, Ghazvini A, Ghanei M, et al. Assessment of Treg/Th17 axis role in immunopathogenesis of chronic injuries of mustard lung disease. Journal of Receptors and Signal Transduction 2016;36(5):531-41.
8. Roos-Engstrand E, Pourazar J, Behndig AF, Bucht A, Blomberg A. Expansion of CD4+ CD25+ helper T cells without regulatory function in smoking and COPD. Respiratory Research 2011;12(1):74.
9. Santegoets SJ, Dijkgraaf EM, Battaglia A, Beckhove P, Britten CM, Gallimore A, et al. Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry. Cancer Immunology, Immunotherapy 2015;64(10):1271-86.
10. Singer BD, King LS, D'Alessio FR. Regulatory T cells as immunotherapy. Frontiers in Immunology 2014;5:46.
11. Letourneau S, Krieg C, Pantaleo G, Boyman O. IL-2- and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets. The Journal of Allergy and Clinical Immunology 2009;123(4):758-62.
12. Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. Journal of Experimental Medicine 2006;203(7):1693-700.
13. Li Z, Li D, Tsun A, Li B. FOXP3+ regulatory T cells and their functional regulation. Cellular & Molecular Immunology 2015;12(5):558.
14. Sawant DV, Vignali DA. Once a Treg, always a Treg? Immunological Reviews 2014;259(1):173-91.
15. Paats MS, Bergen IM, Hoogsteden HC, van der Eerden MM, Hendriks RW. Systemic CD4+ and CD8+ T cell cytokine profiles correlate with GOLD stage in stable COPD. European Respiratory Journal 2012:erj00796-2011.
16. Barcelo B, Pons J, Ferrer J, Sauleda J, Fuster A, Agusti A. Phenotypic characterisation of T-lymphocytes in COPD: abnormal CD4+ CD25+ regulatory T-lymphocyte response to tobacco smoking. European Respiratory Journal 2008;31(3):555-62.
17. Eusebio M, Kuna P, Kraszula L, Kupczyk M, Pietruczuk M. The relative values of CD8+ CD25+ FOXP3brigh Treg cells correlate with selected lung function parameters in asthma. International Journal of Immunopathology and Pharmacology 2015;28(2):218-26.
)